hepat
describ
centuri
th
centuri
connect
made
jaundic
diseas
affect
hepatocyt
term
hepat
greek
mean
inflammatori
diseas
liver
caus
may
numer
sever
type
hepat
identifi
viral
specif
nonspecif
bacteri
toxic
eg
drug
herbal
alcohol
consumpt
food
immunolog
autoimmun
metabol
wilson
diseas
vascular
compromis
hepat
perfus
viral
hepat
affect
hundr
million
individu
worldwid
particularli
develop
countri
howev
incid
high
industri
countri
well
seven
hepat
virus
identifi
thirti
year
period
recent
discoveri
hepat
g
viru
suggest
list
may
complet
yet
accept
terminolog
differenti
hepat
alphabet
b
c
delta
e
f
g
virus
caus
hepat
classifi
two
group
depend
rout
transmiss
thu
e
f
still
poorli
character
virus
orofec
transmiss
virus
transmit
food
shellfish
dirti
water
dirti
hand
contamin
stool
caus
epidem
character
absenc
risk
chronic
infect
second
group
compris
type
b
c
g
virus
transmit
parenter
way
contamin
biolog
fluid
like
blood
semen
infect
character
risk
chronic
evolv
cirrhosi
primari
cancer
liver
use
contamin
syring
drug
abus
blood
blood
product
transfus
transplant
organ
hemodialysi
common
way
virus
acquir
sexual
intercours
particularli
import
rout
transmiss
type
b
viru
hbv
less
commonli
hcv
may
also
transmit
vertic
mother
child
labor
remain
determin
whether
hepat
g
viru
sexual
transmit
viral
hepat
import
public
health
problem
primari
prevent
therefor
mandatori
possibl
vaccin
exist
hepat
b
alon
combin
young
peopl
particular
protect
virus
especi
travel
countri
high
incid
virus
high
standard
hygien
meticul
disinfect
instrument
hospit
environ
nonexchang
syring
drug
addict
practic
lower
significantli
transmiss
rate
virus
alcohol
consumpt
even
moder
quantiti
risk
factor
aggrav
evolut
hepat
lesion
viral
hepat
classifi
alphabeticallyfrom
g
classif
use
predict
cours
diseas
treatment
final
prognosi
hepat
hepat
g
gbcv
like
hepat
c
viru
belong
famili
flavivirida
hepat
present
variou
form
subclin
hepat
usual
affect
children
young
adult
associ
minor
nonspecif
symptom
like
fatigu
abdomin
discomfort
loss
appetit
infect
individu
may
rare
notic
urin
becom
darker
stool
discolor
acut
hepat
present
flu
fever
digest
troubl
abdomin
pain
follow
jaundic
signific
increas
serum
transaminas
urin
darken
stool
discolor
complet
recoveri
case
fulmin
hepat
character
rapid
evolut
result
disastr
hepat
failur
associ
encephalopathi
coma
mortal
approach
fulmin
hepat
requir
liver
transplant
three
virus
b
hbv
c
hcv
hdv
respons
chronic
hepat
patient
chronic
infect
often
asymptomat
may
display
moder
increas
serum
transaminas
patient
infect
hbv
usual
carrier
surfac
antigen
viru
hb
ag
persist
serum
six
month
patient
may
also
coinfect
hdv
viru
hcv
infect
individu
may
present
posit
antibodi
part
viral
genom
antihcv
chronic
hepat
lead
cirrhosi
hbv
patient
mcmahon
hcv
patient
maddrey
chronic
hbvhdv
coinfect
long
term
primari
hepatocarcinoma
liver
develop
cirrhot
hbv
hcv
patient
hepat
caus
hav
infect
benign
condit
case
often
goe
unnot
usual
affect
children
adolesc
young
adult
develop
countri
diseas
sever
year
age
incub
period
day
mean
day
convalesc
period
prolong
children
diseas
subclin
rare
manifest
jaundic
often
associ
simpl
flulik
symptom
adult
jaundic
appear
case
elderli
becom
symptomat
case
recoveri
take
week
hepat
evolv
chronic
fulmin
hepat
rare
one
case
everi
infect
prognosi
good
hepat
b
viru
respons
primari
liver
cancer
case
hepat
b
contagi
diseas
essenti
affect
liver
two
third
infect
adult
present
typic
flulik
symptom
soon
becom
jaundic
remain
case
patient
anicter
elev
serum
transaminas
case
hepat
evolv
fulmin
form
mortal
within
week
begin
jaundic
unfavor
sequel
due
hyperreact
host
immun
system
hb
v
therapi
urgent
liver
transplant
infect
adult
expos
hbv
develop
persist
infect
childhood
case
becom
chronic
natur
histori
chronic
hepat
evolv
four
stage
activ
multipl
viru
immunolog
effort
host
elimin
hbv
usual
unsuccess
hbv
integr
hepat
genom
stop
replic
viru
lower
viral
dna
serum
hbsag
remain
present
although
patient
express
hepat
patholog
consist
either
pattern
chronic
hepat
even
cirrhosi
reactiv
hbv
usual
mutant
type
multipli
aggress
lead
termin
diseas
half
case
induc
cirrhosi
portal
hypertens
final
primari
liver
cancer
hepat
c
chronic
conditionin
infect
individu
due
weak
natur
host
immun
respons
viru
usual
result
blood
transfus
previou
decad
hcv
incid
high
among
drug
abus
hiv
patient
chronic
infect
especi
consum
alcohol
hepat
c
progress
cirrhosi
complic
includ
endstag
liver
diseas
portal
hypertens
hepatocellular
carcinoma
hcv
also
link
spectrum
extrahepat
diseas
thu
roughli
patient
manifest
jaundic
complain
malais
anorexia
abdomin
pain
nonspecif
flulik
symptom
fulmin
hepat
failur
rare
report
hepat
c
often
discov
year
initi
contact
viru
mean
time
appear
cirrhosi
vari
year
mean
approxim
year
initi
contamin
approxim
million
peopl
unit
state
million
peopl
worldwid
infect
hcv
infect
hepat
viru
alway
lead
hepat
lesion
coinfect
hbv
hdv
entail
time
higher
risk
fulmin
hepat
compar
acut
hepat
due
hbv
infect
coinfect
hbv
hdv
lead
increas
risk
chronic
hepat
e
mainli
affect
adolesc
young
adult
frequent
appear
form
epidem
often
massiv
long
last
incub
period
estim
averag
day
diseas
similar
hepat
durat
symptom
last
approxim
two
week
half
infect
asymptomat
run
benign
cours
without
evolv
chronic
hepat
cirrhosi
hev
respons
acut
case
nona
nonb
hepat
develop
countri
pregnant
women
higher
risk
fulmin
cours
mortal
rate
reach
transmiss
viru
mother
child
lead
either
benign
infect
fetu
death
uteru
due
hgv
hepat
g
appear
benign
diseas
viru
present
children
year
evolv
persist
infect
terrault
wright
hgv
yet
demonstr
caus
liver
diseas
associ
hepat
due
infect
hbv
hcv
extrahepat
manifest
acut
hav
infect
less
frequent
hb
v
appear
frequent
patient
protract
diseas
schiff
evanesc
rash
arthalgia
commonli
appear
hepat
aless
commonli
vascul
glomerulonephr
true
arthriti
myocard
optic
neuriti
neuropathi
well
thrombocytopenia
aplast
anemia
also
report
infect
posthepatit
syndrom
character
prolong
malais
abnorm
liver
enzym
persist
igm
antihav
antibodi
describ
extrahepat
find
common
hbv
infect
arthralgia
rash
occur
patient
sever
form
vascul
polyarter
nodosa
may
evolv
either
acut
chronic
hbv
infect
syndrom
typic
present
fever
abdomin
pain
renal
failur
manifest
secondari
vascul
neuropathi
guillainbarr
polyneuropathi
renal
diseas
arthriti
raynaud
phenomenon
chronic
lesser
degre
acut
hbv
infect
associ
immunetyp
glomerulonephr
lead
end
stage
renal
failur
sometim
chronic
hbv
infect
may
associ
autoimmun
hepat
rare
hbv
associ
pancreat
pericard
chronic
hbv
lead
cirrhosi
hepatocellular
carcinoma
mix
type
cryoglobulinemia
prolif
glomerulonephr
polyarter
nodosa
sicca
syndrom
compris
group
diseas
strongli
associ
hcv
infect
hand
autoimmun
thyroid
diseas
skin
lesion
like
porphyria
cutanea
tarda
lichen
planu
aplast
anemia
lymphoma
idiopath
pulmonari
fibrosi
neuropathi
mooren
corneal
ulcer
condit
associ
hepat
c
infect
moreov
incid
diabet
mellitu
appear
higher
among
hcv
patient
hav
small
picornaviru
resembl
poliovirus
viral
capsid
contain
rna
icosahedr
structur
lack
membran
envelop
hav
resist
extern
environ
penetr
organ
oral
rout
multipli
hepatocyt
spread
throughout
intestin
excret
fecal
excret
hbvi
envelop
dna
viru
famili
hepadna
virus
gene
integr
human
hepatocellular
genom
respons
chronic
infect
may
progress
cirrhosi
ultim
hepat
cancer
three
type
viral
particl
virion
sphere
filament
identifi
serum
infect
human
virion
viral
particl
compos
envelop
surfac
protein
nucleocapsid
carri
protein
capsid
viral
dn
sphere
filament
empti
envelop
consist
protein
synthes
excess
viral
replic
empti
envelop
infecti
highli
antigen
activ
host
immun
mechan
viru
hepat
b
contagi
diseas
hbv
present
biolog
fluid
infect
individu
includ
blood
sexual
secret
saliva
urin
milk
howev
data
regard
infect
consist
viral
concentr
serum
semen
moreov
viru
rel
resist
environ
surviv
day
extern
medium
hour
c
min
c
resist
ether
alcohol
extrem
cold
temperatur
hcv
small
rna
viru
belong
flavivirida
famili
member
flavivirus
like
rna
virus
subject
high
frequenc
mutat
exist
form
quasi
speci
infect
individu
maddrey
mani
singlestrand
positivesens
rna
virus
viral
nonstructur
protein
cellular
protein
form
multiprotein
complex
direct
replic
viral
rna
genom
although
mechan
hcv
templat
rna
replic
well
defin
believ
may
follow
similar
pattern
greatest
hindranc
understand
hcv
infect
low
level
hcv
particl
plasma
lack
effici
cell
cultur
system
virusto
date
possibl
grow
hcv
reliabl
effici
laboratori
cell
cultur
cell
deceler
critic
studi
biochem
function
properti
viral
protein
well
understand
step
viral
life
cycl
interact
host
cell
hcv
resist
immun
defens
induc
chronic
infect
known
hcv
block
interferoninduc
antivir
host
respons
thought
respons
failur
interferonbas
treatment
disord
hepat
hdv
viroid
defect
incomplet
viru
multipli
presenc
hbv
viru
hdv
borrow
envelop
hbv
make
capabl
attach
enter
hepatocyt
genom
circular
rna
molecul
replic
autonom
howev
absenc
hbv
act
helper
delta
viru
secret
hepat
cell
hepat
ei
rna
singl
strand
nonenvelop
viru
share
similar
calciviridaealpha
super
group
famili
like
norwalk
rubella
plant
furovirus
spheric
larger
volum
ha
v
unlik
hav
fragil
viru
conserv
requir
storag
c
life
environ
probabl
short
hepat
appear
form
epidem
often
last
long
geograph
e
viru
found
india
former
soviet
union
southeast
asia
mexico
diseas
manifest
similar
hepat
symptom
last
approxim
two
week
hgv
like
thehepat
c
viru
flaviviru
three
type
hgv
gbva
viru
tamarin
monkey
transmiss
human
viceversa
gbvb
gbvc
human
virus
isol
viru
african
patient
discov
hgv
viru
virus
singl
strand
rna
virus
hgv
littl
clinic
signific
diseas
caus
viru
appear
mild
selflimit
hgv
howev
associ
hbv
hcv
infect
hgv
alon
associ
hcv
implic
fulmin
hepat
hepat
found
throughout
world
incid
close
relat
socioeconom
level
countri
gener
found
intertrop
countri
poor
hygien
condit
mostli
affect
children
major
adult
antibodi
viru
age
import
respect
clinic
cours
diseas
themajor
case
present
africa
south
america
middl
east
asia
howev
hav
infect
constitut
major
problem
countri
usual
subclin
mild
serolog
diagnos
region
intermedi
endem
north
america
spain
greec
eastern
europ
countri
south
america
southeast
asia
improv
hygien
condit
lower
incid
infect
mani
western
countri
hepat
b
present
worldwid
endem
vari
greatli
area
high
endem
hbsag
preval
popul
southeast
asia
china
africa
alaska
south
america
middl
east
area
transmiss
take
place
vertic
pregnant
mother
infant
within
famili
parent
children
first
five
year
life
area
intermedi
endem
hbsag
preval
popul
eastern
europ
russia
mediterranean
basin
part
middl
east
japan
area
low
endem
hbsag
preval
popul
north
america
western
europ
transmiss
occur
sexual
intercours
particular
highrisk
group
homosexu
drug
addict
estim
million
person
infect
hcv
worldwid
world
health
organ
precis
estim
hcv
preval
avail
gener
popul
countri
develop
nation
preval
rate
gener
less
among
volunt
blood
donor
less
nation
distinct
region
within
nation
hcv
preval
exce
introduct
blood
screen
antihcv
transfus
relat
case
declin
unit
state
inject
drug
use
common
risk
factor
today
egypt
hcv
preval
vari
highli
endem
area
hcv
infect
preval
among
person
year
age
uncommon
less
year
age
cohort
effect
suggest
timerestrict
exposur
mani
instanc
medic
procedur
yet
confirm
suspect
egypt
nation
campaign
treat
schistosomiasi
respons
fifteen
million
individu
infect
world
wide
hdv
alter
mast
although
epidemiolog
pattern
hdv
similar
hbv
geograph
distribut
alway
similar
thu
high
endem
found
area
high
hbv
preval
except
alaska
alter
mast
intermedi
hdv
preval
found
area
intermedi
high
hbv
preval
low
hdv
preval
found
area
low
intermedi
high
hbv
preval
transmiss
mode
similar
hbv
infect
drug
abus
hemophiliac
receiv
larg
quantiti
blood
increas
risk
sexual
transmiss
hdv
common
comparison
hbv
hepat
eviru
found
india
former
soviet
union
china
southeast
asia
mexico
epidem
sporad
infect
known
occur
countri
endem
countri
outbreak
e
viru
occur
everi
year
nonendem
area
sporad
infect
occur
reservoir
hev
interepidem
period
unknown
overal
casefat
rate
gener
endem
popul
mast
krawczynski
pregnant
women
higher
fatal
rate
fetal
death
even
higher
especi
third
trimest
tsega
et
al
linnen
et
al
hgv
associ
hcv
frequent
found
patient
group
parenter
risk
factor
last
year
new
data
contribut
knowledg
mechan
differ
virus
caus
liver
injuryterrault
wright
hepat
precis
pathogenet
mechan
cell
injuri
unknown
hav
seem
directli
cytotox
tissu
cultur
howev
evid
indic
hepatocyt
injuri
secondari
host
immun
respons
immunohistochem
analysi
reveal
immunoglobulin
hav
antigensin
variou
hepat
cell
recent
discov
hepat
b
immun
respons
host
import
viral
factor
pathogenesi
liver
injuri
word
viru
might
harmless
hepatocyt
destroy
due
intens
reaction
host
hbv
eg
fulmin
hepat
hbv
mutat
especi
specif
precor
genom
region
affect
natur
histori
diseas
well
treatment
outcom
mechan
viral
persist
hepatocellular
injuri
poorli
understood
chronic
hcv
infect
gener
viral
infect
produc
cellular
injuri
direct
cytopath
indirect
immunemedi
injuri
evid
hdv
antigenandhdv
rna
may
directli
cytotox
hepatocyt
autoimmun
may
one
possibl
mechan
liver
diseas
propag
may
partli
explain
differ
sever
seen
hdv
plu
hbv
versu
hbv
alon
mix
mechan
hev
action
direct
hepatocellular
injuri
includ
interfer
product
cellular
macromolecul
alter
cellular
membran
lysosom
permeabl
immunemedi
injuri
includ
lysi
viral
infect
hepatocyt
either
direct
lymphocyt
cytotox
antibodymedi
cytotox
common
clinic
manifest
hepat
list
major
character
acut
orand
chronic
hepat
schiff
featur
mark
asterisk
denot
chronic
quit
help
guid
diagnos
infect
anorexia
malais
fatigu
fever
gener
deterior
weight
loss
cirrhot
habitu
pruritu
xanthomasxanthelasma
malabsorpt
jaundic
hepatomegali
ae
pain
portal
hypertens
ascit
cutan
endocrin
chang
coagulopathi
hypoprothrombinemia
thrombocytopenia
circulatori
chang
hyperdynam
circul
nail
club
vaccin
avail
prevent
hepat
b
vaccin
consid
main
reason
declin
hbv
infect
high
preval
region
studi
come
taiwan
countri
high
hbv
preval
report
declin
hepatocellular
carcinoma
incid
result
gener
popul
vaccin
strategi
last
year
recombin
hbv
vaccin
put
use
worldwid
hbv
vaccin
highli
effect
individu
revaccin
work
fail
respond
primari
vaccin
revaccin
recommend
two
seri
protect
titter
mluml
vaccin
indic
newborn
hbv
posit
mother
hbv
neg
children
high
endem
area
famili
member
hbv
posit
patient
dialysi
patient
frequent
transfus
hbv
neg
social
worker
signific
side
effect
associ
vaccin
three
differ
strategi
use
develop
hav
vaccin
live
attenu
viru
vaccin
inactiv
viru
vaccin
recombin
vaccin
highli
effect
promot
develop
protect
antibodi
howev
recombin
form
appear
least
expens
safest
vaccin
found
costeffect
travel
high
hav
incid
countri
occur
three
time
decad
stay
longer
six
month
concensu
interferon
pegyl
interferon
pegyl
interferon
agent
concensu
interferon
pegyl
interferon
pegyl
interferon
employ
treatment
chronic
infect
compens
uncompens
cirrhosi
nucleosid
analog
approv
use
combin
interferon
appear
greatli
improv
sustain
respons
rate
patient
chronic
hepat
c
lamivudin
recommend
treatment
chronic
hbv
infect
hbv
cirrhosi
mechan
action
entail
inhibit
hbv
dna
polymeras
durat
therapi
year
high
percentag
viral
mutant
first
two
year
treatment
nucleosid
analogu
adenosin
adefovir
approv
chronic
hbv
treatment
especi
resist
lamivudin
entecavir
nucleosid
analog
guanosid
antivir
activ
test
therapi
chronic
hbv
treatment
agent
nucleosid
analog
antivir
test
treatment
chronic
hbv
clevudin
agent
nucleosid
analog
antivir
test
treatment
chronic
hbv
ldeoxythymidin
agent
nucleosid
analog
antivir
test
treatment
chronic
hbv
transgen
mous
model
fulmin
hepat
mingfeng
et
al
two
smallanim
rodent
model
virusinduc
fhf
provid
great
insight
molecular
mechan
virusinduc
fh
f
first
transgen
hbv
model
fhf
hbv
protein
overexpress
second
involv
rna
coronaviru
produc
straindepend
pattern
fh
f
although
transgen
hbsag
model
eleg
mean
dissect
pathogen
mechan
fhf
model
limit
differ
markedli
clinic
situat
replic
viru
exist
anim
model
immun
defect
caus
hepat
c
viru
myungsoo
potenti
role
hcv
infect
evas
immun
surveil
elucid
studi
hcvinfect
chimpanze
experiment
murin
anim
model
develop
anim
model
hepat
b
c
viral
infect
http
english
hadassahorgilpeoplepphanawaldhtmhttp
englishhadassahorgilpeopleppmali
ketzinelhtm
studi
hbv
hcv
develop
new
therapi
slow
evolv
due
lack
practic
conveni
small
anim
model
hbv
anim
model
base
nonprim
provid
use
inform
lack
mani
aspect
human
diseas
goal
group
develop
new
small
anim
model
hbv
infect
model
may
valuabl
investig
viral
infect
hepat
virus
provid
conveni
system
evalu
effect
vaccin
antivir
therapeut
agent
